Alphatec Holdings, Inc. (ATEC) - 10-K Filing Summary
Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Alphatec is a medical technology company focused on the design and development of technology for the surgical treatment of spine disorders. The company operates through wholly-owned subsidiaries Alphatec Spine, SafeOp Surgical, and EOS imaging. Its strategy centers on creating "clinical distinction" through integrated procedural approaches, informatics (Alpha InformatiX platform), and surgeon education.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $611.6 million | $482.3 million | +27% |
| Gross Profit | $424.3 million | $310.2 million | +37% |
| Gross Margin | 69.4% | 64.3% | +5.1 pts |
| Operating Loss | $(136.2) million | $(173.4) million | Improvement |
| Net Loss | $(162.1) million | $(186.6) million | Improvement |
| Cash & Equivalents | $138.8 million | $221.0 million | -$82.2 million |
| Total Debt (Principal) | $589.5 million | $526.6 million | +$62.9 million |
Note: Debt includes $316.3M in Convertible Senior Notes, $200.0M in Braidwell Term Loan, and $63.3M in Revolving Credit Facility.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 19% increase in surgical volume and an 8.0% increase in average revenue per surgery. Surgeon user base grew 18% in 2024.
- Cost of Sales: Increased 9% to $187.3 million, primarily due to higher product volume, partially offset by a decrease in stock-based compensation.
- Operating Expenses: Total operating expenses rose 16% to $560.4 million.
- SG&A: Increased 20% ($76.1M) due to higher compensation costs and investment in the sales channel.
- R&D: Increased 15% ($10.6M) due to personnel expansion and stock-based compensation.
- Litigation Expenses: Decreased 56% ($12.5M) due to reduced legal fees from previously settled matters.
- Restructuring: Increased 352% ($2.5M) primarily due to Paris office relocation and cost rationalization.
- Interest Expense: Increased 50% to $24.9 million due to additional draws on the Braidwell Term Loan.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects continued growth fueled by surgeon adoption of approach-specific procedures (PTP, LTP, Midline ALIF) and the integration of the EOS Insight software platform. The company aims to expand its international footprint in Australia, New Zealand, and Japan.
Liquidity: The company reported a net cash burn of $82.1 million in 2024. Management believes existing cash ($138.8M), cash from operations, and available borrowings under the Revolving Credit Facility are sufficient to fund operations for at least 12 months.
Key Risks:
- Profitability: The company has a history of net losses and an accumulated deficit of $1.3 billion; future profitability is not guaranteed.
- Debt Covenants: Loan agreements contain financial covenants; failure to comply could result in default and acceleration of debt.
- Regulatory: Products are subject to FDA regulation; delays in clearance or adverse regulatory actions could impact sales.
- Supply Chain: Reliance on third-party manufacturers and a single supplier (Invibio) for PEEK raw materials.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $82M annual cash burn against current cash reserves and debt capacity.
- Debt Maturity Profile: Review the maturity dates of the $316M Convertible Notes (2026) and $200M Term Loan (2028) and associated interest obligations.
- Inventory Valuation: Assess the $175.3M inventory balance and the $15.4M charge for excess/obsolete inventory, given the risk of obsolescence in specialized implants.
- Stock-Based Compensation: Monitor the $73.3M SBC expense and its impact on future dilution and operating margins.
- International Expansion: Evaluate the progress and profitability timeline of the nascent international operations in Japan, Australia, and New Zealand.